(3R,4S,5S,6R,7R,9R,10S,11S,12R,13S,14R)-14-ethyl-7,10,12,13-tetrahydroxy-6-((2S,3R,4S,6R)-3-hydroxy-4-((2-hydroxy-2-methylpropyl)(methyl)amino)-6-methyltetrahydro-2H-pyran-2-yloxy)-4-((2S,4S,6S)-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yloxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecan-2-one | 1313716-53-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3R,4S,5S,6R,7R,9R,10S,11S,12R,13S,14R)-14-ethyl-7,10,12,13-tetrahydroxy-6-((2S,3R,4S,6R)-3-hydroxy-4-((2-hydroxy-2-methylpropyl)(methyl)amino)-6-methyltetrahydro-2H-pyran-2-yloxy)-4-((2S,4S,6S)-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yloxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecan-2-one
• 英文别名: (3R,4S,5S,6R,7R,9R,10S,11S,12R,13S,14R)-14-ethyl-7,10,12,13-tetrahydroxy-6-[(2S,3R,4S,6R)-3-hydroxy-4-[(2-hydroxy-2-methylpropyl)-methylamino]-6-methyloxan-2-yl]oxy-4-[(2S,4S,6S)-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one
• CAS: 1313716-53-8
• 化学式: C₄₀H₇₅NO₁₃
• 分子量: 778.034
• InChiKey: UQXKKEVJGSFAME-OWFFPJLUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  54
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.97
• 拓扑面积：
  197
• 氢给体数：
  6
• 氢受体数：
  14

反应信息

• 作为产物：
  描述：

  红霉素 在 甲醇 、 4-二甲氨基吡啶 、 sodium tetrahydroborate 、 碘 、 sodium acetate 作用下， 以 二氯甲烷 为溶剂， 生成 (3R,4S,5S,6R,7R,9R,10S,11S,12R,13S,14R)-14-ethyl-7,10,12,13-tetrahydroxy-6-((2S,3R,4S,6R)-3-hydroxy-4-((2-hydroxy-2-methylpropyl)(methyl)amino)-6-methyltetrahydro-2H-pyran-2-yloxy)-4-((2S,4S,6S)-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yloxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecan-2-one
  参考文献：
  名称：

  The role of the 4′′-hydroxyl on motilin agonist potency in the 9-dihydroerythromycin series

  摘要：

  The role of the erythromycin 4 ''-hydroxyl group has been explored on the motilin agonist potential in the 9-dihydroerythromycin series of motilides. The compounds show potencies 2- to 4-fold superior to the corresponding hydroxylated compounds. The relationship is maintained when the 9-hydroxyl is alkylated to generate the corresponding 4 ''-deoxy-9-O-acetamido-9-dihydroerythromycins. However, concomitant with this increase in potency is an increase in hERG inhibition. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.078

文献信息

• The role of the 4′′-hydroxyl on motilin agonist potency in the 9-dihydroerythromycin series
  作者：Yaoquan Liu、Christopher W. Carreras、Mark Claypool、David C. Myles、Simon J. Shaw

  DOI：10.1016/j.bmcl.2011.04.078

  日期：2011.6

  The role of the erythromycin 4 ''-hydroxyl group has been explored on the motilin agonist potential in the 9-dihydroerythromycin series of motilides. The compounds show potencies 2- to 4-fold superior to the corresponding hydroxylated compounds. The relationship is maintained when the 9-hydroxyl is alkylated to generate the corresponding 4 ''-deoxy-9-O-acetamido-9-dihydroerythromycins. However, concomitant with this increase in potency is an increase in hERG inhibition. (C) 2011 Elsevier Ltd. All rights reserved.